This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.

Learn how Raman microscopy can help solve some of the biggest challenges in 3D imaging and microparticle analysis.

Sir Andrew Dillion will be stepping down from his role as chief executive of NICE next year, after holding his position for 20 years.

The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.

XTANDI^® sNDA seeks to add an indication for men with prostate cancer that’s spread but is sensitive to hormone therapy.